Profile data is unavailable for this security.
About the company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
- Revenue in USD (TTM)377.71m
- Net income in USD-132.53m
- Incorporated2017
- Employees436.00
- LocationBeam Therapeutics Inc238 Main StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 327-8775
- Fax+1 (302) 655-5049
- Websitehttps://beamtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.75bn | 246.00 | 13.34 | 3.40 | 10.82 | 2.84 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Catalyst Pharmaceuticals Inc | 398.20m | 71.41m | 1.77bn | 167.00 | 24.61 | 4.14 | 16.96 | 4.44 | 0.6092 | 0.6092 | 3.56 | 3.62 | 0.9417 | 4.63 | 12.45 | 2,384,455.00 | 16.89 | 25.42 | 20.06 | 29.81 | 86.95 | 85.63 | 17.93 | 30.87 | 2.68 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 27.96m | -160.28m | 1.79bn | 154.00 | -- | 19.07 | -- | 64.00 | -2.04 | -2.04 | 0.3491 | 0.9768 | 0.188 | -- | 4.52 | 181,577.90 | -107.75 | -40.21 | -156.49 | -47.99 | 96.97 | -- | -573.17 | -374.75 | 3.36 | -13.94 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Inhibrx Inc | 1.80m | -241.36m | 1.79bn | 166.00 | -- | 37.35 | -- | 996.19 | -5.03 | -5.03 | 0.0382 | 0.9184 | 0.006 | -- | 3.53 | 10,843.37 | -80.07 | -77.06 | -93.12 | -93.91 | -- | -- | -13,318.17 | -1,590.91 | -- | -11.00 | 0.8263 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Myriad Genetics, Inc. | 753.20m | -263.30m | 1.81bn | 2.70k | -- | 2.29 | -- | 2.40 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Fusion Pharmaceuticals Inc | 2.07m | -94.90m | 1.82bn | 113.00 | -- | 7.67 | -- | 880.06 | -1.47 | -1.47 | 0.0315 | 2.79 | 0.0082 | -- | 60.82 | 18,300.88 | -37.59 | -35.45 | -40.07 | -38.55 | -- | -- | -4,588.83 | -7,206.24 | -- | -- | 0.1352 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.85bn | 93.00 | -- | 4.07 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Beam Therapeutics Inc | 377.71m | -132.53m | 1.88bn | 436.00 | -- | 1.89 | -- | 4.96 | -1.87 | -1.87 | 4.90 | 12.02 | 0.2697 | -- | -- | 866,305.10 | -9.46 | -24.54 | -11.17 | -29.26 | -- | -- | -35.09 | -211.96 | -- | -- | 0.0005 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.89bn | 383.00 | -- | 2.53 | -- | 64.14 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.90bn | 88.00 | -- | 4.49 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.91bn | 112.00 | -- | 3.44 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.05bn | 7.70k | -- | -- | 19.27 | 0.8223 | -0.5642 | -0.5642 | 11.52 | -0.1381 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 0.8617 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Data as of May 07 2024. Currency figures normalised to Beam Therapeutics Inc's reporting currency: US Dollar USD
54.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 8.18m | 10.02% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 6.97m | 8.53% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.67m | 6.95% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.62m | 5.65% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 4.11m | 5.03% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 3.87m | 4.74% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.83m | 4.69% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 2023 | 3.08m | 3.77% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 2.36m | 2.89% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.58m | 1.93% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
